Metropolis Healthcare Q2 net profit rises 13% on TruHealth, specialty portfolio growth

Diagnostic chain Metropolis Healthcare Ltd on Tuesday (November 4) reported a 13.2% year-on-year increase in net profit to ₹53 crore for the quarter ended September 2025, compared with ₹47 crore in the same period last year.

Revenue for the quarter grew 22.7% year-on-year to ₹429 crore from ₹349.8 crore in Q2FY25. Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 20.5% year-on-year to ₹108.6 crore, up from ₹90.1 crore in the same period last year. The company’s EBITDA margin stood at 25.3%, slightly down from 25.7% in Q2FY25.

The company's patient and test volumes grew 11% and 12% year-on-year, respectively. Both B2C and B2B revenues rose 16% and 33% YoY, reflecting robust demand across the business segments.

Also Read: Metropolis Healthcare to deepen North India footprint for the next growth phase

Revenue per patient (RPP) and revenue per test (RPT) increased 11% and 10% YoY, supported by brand trust, premium offerings, and rising demand for preventive and specialty testing. TruHealth wellness and Specialty portfolios recorded strong growth, with ~24% and ~33% YoY increases, respectively, underscoring momentum in high-value services.

Geographically, North India’s revenue contribution rose to 19% from 17% in Q1FY26, while Tier III cities posted 13% revenue growth, highlighting the company’s expanding reach.

Core Diagnostics achieved positive PAT within two quarters of acquisition, attaining high single-digit EBITDA margins in Q2. Subsidiaries DAPIC (Dehradun) and Scientific Pathology (Agra) continued to outperform the company’s average margin levels.

Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare, said, "The swift turnaround of Core Diagnostics and the strong performance of our recent acquisitions in Dehradun and Agra reaffirm the strength of our integration strategy and our ability to create sustainable value through local excellence.

Also Read: Metropolis Healthcare targets over 12% organic growth in FY26

As we advance genomics and AI-enabled innovation alongside digital transformation, we’re driving rapid adoption that expands access to quality diagnostics and accelerates the sector’s shift from unorganised to organised players. Our focus remains on shaping a future-ready Metropolis — a trusted, science-led organisation that sets new benchmarks for quality, care, and value creation."

Metropolis Healthcare has declared an interim dividend of ₹4 per equity share for the financial year 2025-26. Each equity share has a face value of ₹2. The record date for the purpose of payment of the interim dividend is set as November 11, 2025. The dividend will be dispatched or credited to shareholders within 30 days of its declaration.

Shares of Metropolis Healthcare Ltd ended at ₹2,028.60, up by ₹24.15, or 1.20%, on the BSE.

Also Read: Metropolis Healthcare Q4 net slips 19% but revenue up 4%; TruHealth shines